NEUROASPIS® plp10 is a cocktail food supplement oral formula that has been specifically designed to overcome the well known biochemical deficiencies of the MS patients which are found related to the disease pathophysiology including recovery; and it has been tested through a proof of concept clinical study performed from July 2007 until December 2010. The preparation has been specifically designed by a team of three committed and highly specialized scientists (Dr. Patrikios I. Mr. Loukaides G. and Dr. Pantzaris M.) in the field of Neurology, Medical Biochemistry, Immunology, Lipidology,  and Clinical Nutrition and produced in accordance to the innovative method of treatment philosophy and approach, the systems medicine, through systems biology.


A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial >>


More than forty five Supportive Statements and Publications about NEUROASPIS since 1997 >>


08.11.2018 Neuroaspis presented at Neurowoche 2018/DGN Congress in Berlin

Neuroaspis was presented at DGN Congress during Neurowoche 2018, 30/10-3/11 in Berlin. DGN Congress is one of the largest German-speaking medical congresses and one of the three most visited neurological congresses worldwide. https://www.dgn.org/rubrik-dgn/der-dgn-kongress

23.10.2018 Neuroaspis was presented at ECTRIMS Berlin 2018

NEUROASPIS® was presented at  ECTRIMS Berlin 2018, the 34th Congress of the European Committee for Treatment and Research of Multiple Sclerosis, which was held between 10-12 October in Berlin. ECTRIMS is the world’s largest annual international conference devoted to basic and clinical research in Multiple Sclerosis.